ADC Therapeutics SA announced that, on December 15, 2022, Robert A. Schmidt informed the Company of his resignation as the Company's Chief Accounting Officer, effective December 30, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.55 USD | -5.20% |
|
-6.25% | +53.61% |
30/05 | Cantor Fitzgerald Initiates ADC Therapeutics at Overweight Rating | MT |
07/05 | HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+53.61% | 25Cr | |
+16.45% | 12TCr | |
+21.96% | 12TCr | |
+23.73% | 2.7TCr | |
-20.05% | 2.04TCr | |
-16.28% | 1.59TCr | |
-16.52% | 1.64TCr | |
-44.35% | 1.56TCr | |
+63.91% | 1.49TCr | |
+2.52% | 1.36TCr |
- Stock Market
- Equities
- ADCT Stock
- News ADC Therapeutics SA
- ADC Therapeutics SA Announces Resignation of Robert A. Schmidt as Company’S Chief Accounting Officer, Effective December 30, 2022